Genovis AB - Company Profile
Powered by 
All the data and insights you need on Genovis AB in one report.
$295
- Save hours of research time and resources with
our up-to-date Genovis AB Strategy Report
- Understand Genovis AB position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Genovis AB (Genovis) develops, produces and markets enzyme products, which facilitate the development and quality control of biological drugs. The company’s products are used for antibody molecules analysis to identify and characterize proteins, antibody-based biotherapeutics; monoclonal antibodies, antibody drug conjugates and biosimilars. Its SmartEnzymes product portfolio encompasses Fabricator (IdeS), Gingiskhan (KGP), Fabulous (SpeB), Glycinator (EndoS49), Fabricator Z (IdeZ), Gingisrex (Rgp) and IgGzero (EndoS). Genovis also offers antibody fragmentation services for different species and subclasses of Immunoglobulin G antibodies. The company offers its products to researchers at pharmaceutical and biotechnology companies, and academic institutions. It has presence in the US; Europe. Genovis is headquartered in Lund, Sweden.
Headquarters
Sweden
Address
Medicon Village, Scheelevagen 2, Lund, 22363
Website
www.genovis.com
Telephone
46 46 101230
No of Employees
37
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GENO (STO)
Revenue (2022)
$10.1M
10.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-54.8%
(2022 vs 2021)
Market Cap*
$161.9M
Net Profit Margin (2022)
XYZ
-59.0%
(2022 vs 2021)
* As of and is in US$
Genovis AB premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| - | - | Fabricator |
| Fabricator (IdeS) | Antibody Fragmentation Services | Fabalactica |
| Fabricator Z (IdeZ) | Fabulous | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | New Products/Services | In June, the company launched innovative IgM-Specific Protease with wide-ranging applications in life science markets. |
| 2023 | Contracts/Agreements | In May, the company enter into a collaboration agreement with ArcticZymes to accelerate growth in China. |
| 2022 | Contracts/Agreements | In August, the company entered into a licensing and supply agreement with new bioprocess customer for the supply of SmartEnzymes. |
Competitor Comparison
| Key Parameters | Genovis AB | Thermo Fisher Scientific Inc | Agilent Technologies Inc | Bio-Rad Laboratories Inc | Global Life Sciences Solutions USA LLC |
|---|---|---|---|---|---|
| Headquarters | Sweden | United States of America | United States of America | United States of America | United States of America |
| City | Lund | Waltham | Santa Clara | Hercules | Marlborough |
| State/Province | - | Massachusetts | California | California | Massachusetts |
| No. of Employees | 37 | 130,000 | 18,400 | 8,200 | 10,000 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Torben Jorgense | Chairman | Executive Board | 2020 | 71 |
| Fredrik Olsson | Chief Executive Officer | Senior Management | - | 52 |
| Magnus Langberg | Chief Financial Officer | Senior Management | 2022 | 52 |
| Helen Carlsson Nyhlen | Vice President - Application Development and Support | Senior Management | - | 59 |
| Linda Andersson | Vice President - Production | Senior Management | - | 47 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer